Skip to main content
. Author manuscript; available in PMC: 2013 Nov 19.
Published in final edited form as: Expert Rev Hematol. 2008 Dec;1(2):10.1586/17474086.1.2.161. doi: 10.1586/17474086.1.2.161

Table 1.

Clinical experience with single-agent 5-azacytdine in myelodysplastic syndrome and acute myelogenous leukemia.

n Complete response (n [%]) Partial response (n [%]) Hematologic improvement (n [%]) Overall response rate (n [%]) Ref.
CALGB 8421 iv. azacitidine 48 7 (15) 1 (2) 13 (27) 21 (44) [44]
CALGB 8921 sc. azacytidine 70 12 (17) 0 (0) 16 (23) 28 (40) [44]
Updated CALGB 9221 sc. azacytidine 99 10 (10) 1 (1) 36 (36) 47 (47) [43,44]
CALGB 9221 sc. azacytidine crossover after observation 51 3 (6) 2 (4) 13 (25) 18 (35) [43,44]

CALGB: Cancer and Leukemia Group B; iv.: Intravenous; sc.: Subcutaneous.